MRD-Guided Chemotherapy After Pancreatic Cancer Surgery
Part of Cancer clinical trials.
This trial tests whether using a special blood test (MRD) to guide chemotherapy after pancreatic cancer surgery can improve outcomes. It is for people who have had their cancer completely removed and are ready for standard follow-up therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You had surgery to remove pancreatic ductal adenocarcinoma (the most common type) and the cancer was stage I-III with clear margins (R0 resection).
- Your surgery was less than 12 weeks ago.
- You have fully recovered from surgery and can receive chemotherapy.
- You have enough tumor tissue from your surgery to be tested for MRD (minimal residual disease).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at using a special blood test (ctDNA MRD) to track how well the tumor responds to chemotherapy before surgery for pancreatic cancer. It may help doctors decide if the treatment is working and guide next steps.
This trial studies a new blood test that looks for cancer-specific immune cells after surgery for pancreatic cancer. It aims to see if the test can detect any remaining cancer cells earlier than standard methods, which could help guide further treatment decisions.
This trial tests whether using a blood test for tumor DNA (ctDNA) can help decide who needs more chemotherapy after surgery for advanced stomach cancer. The goal is to personalize treatment and avoid unnecessary side effects.
This study tracks tiny pieces of cancer DNA in your blood after pancreatic cancer surgery to see if they can predict whether cancer might come back. Researchers will draw blood several times over the next year to test this new monitoring approach.
This trial is for people who had surgery for pancreatic cancer and are now deciding on maintenance therapy. A special blood test (ctDNA) may help doctors choose the best follow-up treatment to prevent the cancer from coming back.
This study looks at whether a blood test for leftover cancer cells (called MRD) after stomach cancer surgery can help guide treatment. It is for people with a certain type of stomach cancer that has spread to nearby tissues but not to distant organs, and who are having surgery as their first treatment.
Hear when a new Pancreatic Adenocarcinoma Resectable trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.